These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30139653)

  • 1. Aluminum in vaccines: Does it create a safety problem?
    Principi N; Esposito S
    Vaccine; 2018 Sep; 36(39):5825-5831. PubMed ID: 30139653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reviewing the association between aluminum adjuvants in the vaccines and autism spectrum disorder.
    Boretti A
    J Trace Elem Med Biol; 2021 Jul; 66():126764. PubMed ID: 33930617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system.
    Gherardi RK; Crépeaux G; Authier FJ
    Autoimmun Rev; 2019 Jul; 18(7):691-705. PubMed ID: 31059838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants.
    Masson JD; Crépeaux G; Authier FJ; Exley C; Gherardi RK
    J Inorg Biochem; 2018 Apr; 181():87-95. PubMed ID: 29307441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA).
    Ameratunga R; Gillis D; Gold M; Linneberg A; Elwood JM
    J Allergy Clin Immunol Pract; 2017; 5(6):1551-1555.e1. PubMed ID: 28888842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aluminium adjuvant exposure through vaccines in France in 2018].
    Angrand L; Elnar AA; Authier FJ; Gherardi RK; Crépeaux G
    Ann Pharm Fr; 2020 Mar; 78(2):111-128. PubMed ID: 32081303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aluminum adjuvants of vaccines injected into the muscle: Normal fate, pathology and associated disease.
    Gherardi RK; Aouizerate J; Cadusseau J; Yara S; Authier FJ
    Morphologie; 2016 Jun; 100(329):85-94. PubMed ID: 26948677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of binding of aluminum-containing adjuvants to Haemophilus influenzae type b and meningococcal group C conjugate vaccines and components.
    Otto RB; Burkin K; Amir SE; Crane DT; Bolgiano B
    Biologicals; 2015 Sep; 43(5):355-62. PubMed ID: 26194164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
    Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
    J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome].
    Gherardi RK
    Rev Neurol (Paris); 2003 Feb; 159(2):162-4. PubMed ID: 12660567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminum vaccine adjuvants: are they safe?
    Tomljenovic L; Shaw CA
    Curr Med Chem; 2011; 18(17):2630-7. PubMed ID: 21568886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?
    Tomljenovic L; Shaw CA
    J Inorg Biochem; 2011 Nov; 105(11):1489-99. PubMed ID: 22099159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.
    Exley C; Swarbrick L; Gherardi RK; Authier FJ
    Med Hypotheses; 2009 Feb; 72(2):135-9. PubMed ID: 19004564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods to Prepare Aluminum Salt-Adjuvanted Vaccines.
    Thakkar SG; Cui Z
    Methods Mol Biol; 2017; 1494():181-199. PubMed ID: 27718194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children.
    Glanz JM; Newcomer SR; Daley MF; McClure DL; Baxter RP; Jackson ML; Naleway AL; Lugg MM; DeStefano F
    Vaccine; 2015 Nov; 33(48):6736-44. PubMed ID: 26518400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.
    Mitkus RJ; King DB; Hess MA; Forshee RA; Walderhaug MO
    Vaccine; 2011 Nov; 29(51):9538-43. PubMed ID: 22001122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum inclusion macrophagic myofasciitis: a recently identified condition.
    Gherardi RK; Authier FJ
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):699-712. PubMed ID: 14753387
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.